Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery

Coronary Artery Disease

Volumn 25, Issue 8, 2014, Pages 678-684

  Qu, Yang ^a,b   Wei, Lixin ^a   Zhang, Haiqing ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Acute heart failure; Atorvastatin reload; Major adverse cardiac events; Noncardiac emergency surgery

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; INTERLEUKIN 6; PLACEBO; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ACUTE HEART FAILURE; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EMERGENCY SURGERY; FEMALE; HEART PROTECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME; ACUTE DISEASE; ADVERSE EFFECTS; BLOOD; CHI SQUARE DISTRIBUTION; CHINA; COMPLICATION; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EMERGENCY; EPIDEMIOLOGY; HEART FAILURE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDY; RISK FACTOR; SINGLE BLIND PROCEDURE; STATISTICAL MODEL; SURGERY; TIME FACTOR;

ACUTE DISEASE; AGED; ANTI-INFLAMMATORY AGENTS; ATORVASTATIN CALCIUM; BIOMARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHINA; CORONARY ARTERY DISEASE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EMERGENCIES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; SINGLE-BLIND METHOD; SURGICAL PROCEDURES, OPERATIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927594742     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000143     Document Type: Article

References (27)

1. Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990;72:153-184.
2. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007;116:e418-e499.
3. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
4. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e426-e579.
5. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-2306.
6. Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, Caramelli B. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004;39:967-975, discussion 975-976.
7. O'Neil-Callahan K, Katsimaglis G, Tepper MR, Ryan J, Mosby C, Ioannidis JP, Danias PG. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the statins for risk reduction in surgery (StaRRS) study. J Am Coll Cardiol 2005;45:336-342.
8. Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek MR, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009;361:980-989.
9. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006;114:1455-1461.
10. Uettwiller-Geiger D, Wu AH, Apple FS, Jevans AW, Venge P, Olson MD, et al. Multicenter evaluation of an automated assay for troponin I. Clin Chem 2002;48:869-876.
11. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.
12. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-3968.
13. Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005;96:5G-10G.
14. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-1598.
15. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 2009;54:558-565.
16. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
17. Van Diepen S, Bakal JA, McAlister FA, Ezekowitz JA. Mortality and readmission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation 2011;124:289-296.
18. Xu-Cai YO, Brotman DJ, Phillips CO, Michota FA, Tang WH, Whinney CM, et al. Outcomes of patients with stable heart failure undergoing elective noncardiac surgery. Mayo Clin Proc 2008;83:280-288.
19. Stypmann J, Schubert A, Welp H, Schulte H, Assmann G, Breithardt G, Nofer JR. Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Clin Cardiol 2008;31:478-481.
20. Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother 2007;8:3061-3068.
21. Dawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol 1996;57:37-44.
22. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. Cardiovasc Pathol 1999;8:133-139.
23. Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy - part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg 2010;44:241-251.
24. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, et al. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 2012;125:1979-1987.
25. Hahn JY, Kim HJ, Choi YJ, Jo SH, Kim HJ, Lee S, et al. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2011;162:1026-1033.
26. DiNicolantonio JJ, Lavie CJ, Serebruany VL, O'Keefe JH. Statin wars: the heavyweight match - atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med 2013;125:7-16.
27. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-1278.